Beximco Pharmaceuticals has begin the export Methocarbamol tablets to the US, generic equivalent to Auxilium Pharmaceuticals’ muscle relaxant Robaxin tablets, 500mg and 700mg. This product is a generic equivalent to Auxilium Pharmaceuticals’ muscle relaxant Robaxin tablets, which is for pain relief associated with acute musculoskeletal conditions. The first consignment was delivered on 21 April 2018.
The export of Methocarbamol tablets marks the third product to be exported by Beximco Pharma to the US, following the successful launch of Carvedilol and Sotalol in August 2016 and November 2017, respectively. According to IQVIA market data, the US market for Methocarbamol is currently valued at USD 23.37 million.
Nazmul Hassan MP, Managing Director of Beximco Pharmaceuticals, said: “The export of our third product to the US further builds our presence in the world’s largest pharmaceutical market. We continue to focus on growing our portfolio in the US, which we believe will be a major export market for Beximco Pharma in the coming years. We remain focused on our strategic goal to bring high quality, differentiated products to both developed and key emerging markets to create value for our customers and shareholders.”